A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Phase 1/2 Completed 32 enrolled PegBio Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The trial is conducted in a single-center, randomized, double-blind, placebocontrolled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) characteristics, efficacy and immunogenicity of PB-119 injection in Chinese obese subjects.

Timeline

Start: 2024-05-27
Primary completion: 2024-11-16
Completion: 2024-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PB-119	Peptide	—	Subcutaneous

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Summary

Timeline

Drugs

Indications